Patents by Inventor Ali Mukherjee
Ali Mukherjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230062274Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.Type: ApplicationFiled: June 30, 2022Publication date: March 2, 2023Applicant: Laboratory Corporation of America HoldingsInventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
-
Patent number: 11401344Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.Type: GrantFiled: October 22, 2018Date of Patent: August 2, 2022Assignee: Laboratory Corporation of America HoldingsInventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
-
Patent number: 10775382Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.Type: GrantFiled: August 21, 2017Date of Patent: September 15, 2020Assignee: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Publication number: 20190055319Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.Type: ApplicationFiled: October 22, 2018Publication date: February 21, 2019Applicant: Laboratory Corporation of America HoldingsInventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
-
Publication number: 20180164319Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.Type: ApplicationFiled: August 21, 2017Publication date: June 14, 2018Applicant: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Patent number: 9766242Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex and the presence and/or amount of p95 in a sample. The invention also provides antibodies specific for Her-3.Type: GrantFiled: July 17, 2015Date of Patent: September 19, 2017Assignee: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Publication number: 20170082626Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.Type: ApplicationFiled: June 15, 2016Publication date: March 23, 2017Applicant: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Publication number: 20160061839Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.Type: ApplicationFiled: July 17, 2015Publication date: March 3, 2016Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Patent number: 9110066Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.Type: GrantFiled: November 7, 2012Date of Patent: August 18, 2015Assignee: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Publication number: 20140370523Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.Type: ApplicationFiled: July 2, 2014Publication date: December 18, 2014Applicant: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Patent number: 8349574Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.Type: GrantFiled: January 15, 2010Date of Patent: January 8, 2013Assignee: Laboratory Corporation of America HoldingsInventors: Michael Bates, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Stephen J. Williams
-
Patent number: 8198031Abstract: Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.Type: GrantFiled: March 12, 2007Date of Patent: June 12, 2012Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Yui, Sharat Singh, Hossein Salimi-Moosavi, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Ali Mukherjee
-
Publication number: 20100291594Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.Type: ApplicationFiled: January 18, 2010Publication date: November 18, 2010Applicant: Laboratory Corporation of America HoldingsInventors: Po-Ying CHAN-HUI, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Publication number: 20100233732Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.Type: ApplicationFiled: January 15, 2010Publication date: September 16, 2010Applicant: Laboratory Corporation of America HoldingsInventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
-
Publication number: 20100210034Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.Type: ApplicationFiled: January 15, 2010Publication date: August 19, 2010Applicant: LABORATORY CORPORATION OF AMERICA HOLDINGSInventors: MICHAEL BATES, ALI MUKHERJEE, GORDON PARRY, JEFF SPERINDE, JENNIFER W. COOK, GUNDO DIEDRICH, LAURIE GOODMAN, STEPHEN J. WILLIAMS
-
Patent number: 7648828Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.Type: GrantFiled: January 21, 2005Date of Patent: January 19, 2010Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Publication number: 20090111127Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers.Type: ApplicationFiled: October 2, 2007Publication date: April 30, 2009Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Publication number: 20090011440Abstract: The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.Type: ApplicationFiled: July 21, 2008Publication date: January 8, 2009Applicant: MONOGRAM BIOSCIENCES, INC.Inventors: Ali Mukherjee, Mengxiang Tang, Harprit S. Pannu, Po-Ying Chan-Hui, Sharat Singh
-
Publication number: 20080233602Abstract: Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.Type: ApplicationFiled: March 12, 2007Publication date: September 25, 2008Inventors: Po-Ying Chan-Yui, Sharat Singh, Hossein Salimi-Mossavi, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Ali Mukherjee
-
Patent number: RE44437Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.Type: GrantFiled: January 18, 2012Date of Patent: August 13, 2013Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh